This represents an advantage compared to international DAs, which do not differentiate between BRCA1 and BRCA2 mutation carriers with and without a history of BC [72, 73], which address a broader target group of women with an increased risk of BC and/or OC [59–61, 64, 74, 75], and which primarily tackle either the risks of BC [59, 64] or OC [60, 63, 74–76]. Here, BRCA2 is linked to breast cancer.